Biogen reaches licensing deal with Xbrane for potential biosimilar to Cimzia
Biogen will obtain exclusive global regulatory, manufacturing, and commercial rights to Xcimzane, along with the marketing authorisation
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Feb 22
Biogen will obtain exclusive global regulatory, manufacturing, and commercial rights to Xcimzane, along with the marketing authorisation
08 Feb 22
Abbott's investigational dual-chamber pacemaker is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle…
07 Feb 22
The FDA approval of Enjaymo is based on positive results from the Phase 3 CARDINAL trial, a 26-week…
07 Feb 22
With the DCGI authorisation, Sputnik Light will be included in India's national vaccine portfolio, joining Sputnik V, which…
04 Feb 22
The collaboration will combine Plexium’s novel technology platform with Amgen’s early discovery expertise to discover new therapeutic agents
04 Feb 22
Novavax’ adjuvanted Covid-19 vaccine, Nuvaxovid, is the first protein-based Covid-19 vaccine to receive market authorisation in Great Britain
03 Feb 22
Omega 3 supplements are experiencing a revival, with health benefits that cannot be ignored. We speak to experts…
03 Feb 22
We focus on the medical potential of proteins and peptides and how the use of nanotechnology can help…
03 Feb 22
Restasis is a commonly prescribed immunomodulator that helps to increase tear production in patients with keratoconjunctivitis sicca, commonly…
03 Feb 22
If authorised, the Pfizer-BioNTech Covid-19 vaccine would be the first Covid-19 vaccine available for paediatric populations aged below…